ID drugs Flashcards

1
Q

Vancomycin MOA and coverage

A
  • Glycopeptide that inhibits bacterial cell wall synthesis by binding to d-alanyl-d-alanine cell wall precursor and blocking
  • Vanc only covers gram positive bacteria, including staph (MRSA), streptococci, enterococci (not VRE) and C. DIff
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

When should you consider an alternative drug fro MRSA?

A

If the MIC is >=2mcg/mL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Vanc dosing including CrCl dose adjustments

A
  • IV 15-20 mg/kg q8-12 hours
  • Dose is based on actual body weight
  • CrCl 20-49 q24h dosing
  • C.Diff
    • 125-500 QID for 10 days (upper end used for severe complicated disease)
    • No dose adjustment for renal impairment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Vanco warnings, SEs, and monitoring

A
  • Ototoxicity and nephrotoxicity
  • PO used only for C.Diff colitis and enterocolitis not absorbed systemically
  • Infusion reaction and red mans syndrome minimum rate of infusion is 1 gram/ hour
  • Monitoring: renal function, trough serum concentrations at steady state generally 30 minutes before the 4th or 5th dose
  • Goal trough 15-20 mcg.mL: pneumonia, endocarditis, osteomyelitis, meningitis, bacteremia
  • Goal trough other infections: 10-15 mcg/mL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lipoglycopeptides what is the suffix and what is the MOA

A
  • vancin
  • Inhibit bacterial cell wall synthesis by 1) binding to D-alanyl-D-alanine portion of the cell wall, blocking polymerization and cross-linking of peptidoglycan and 2) disrupting bacterial membrane potential and changing cell permeability
  • Concentration dependent
  • Similar coverage as vanc but only IV and no C. DIff
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

televancin: what is it approved for?

Safety and Warnings

A
  • Vibativ
  • Approved for complicated skin and soft tissue infections (SSTI) and hospital acquired and ventilator associated pneomonia
  • Fetal risk: obtain pregnancy test prior to starting therapy, nephrotoxicity increase in mortality with pre-exisiting moderate to severe renal impairment (CrCl<=50 mL/min) when compared to vanc
  • COntrainidicated: with concurrent use of IV unfractionated heparin (UFH)
  • Warnings: falsely elevated coagulation tests (aPTT, PT, INR), but does not increase bleeding risk, red man syndrome: give over 30 minutes, QT prolongation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Oritavancin contraindications and approved treatment

Dalbavancin:

A
  • Orbactiv
  • Approved for SSTIs
  • Use of IV UFH for 120 hours (5 days) after orivancin administration due to false elevation in aPTT
  • Can cause falsely elevated PT/INR for up to 12 hours and aPTT for up to 120 hours
  • Orivancin: use a different antibiotic if osteomyelitis is confirmed or suspected
  • Dalbavancin (Dalvance): SSTIs: Infusion reaction with rapid infusion, Increased ALT > 3 x the ULN
  • Infusion site reaction for both red man, N/V/D, rash, HA
  • Extremely long half life allows single dose regimen for both
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Vancomycin glycopeptide, drug interactions

A
  • Risk of nephrotoxicity is increased when other nephro drugs are use (AMGs, ampho B, cisplatin, polymyxins, cyclosporine, tacrolimus, loop diuretics, NSAIDs, radiocontrast dye.
  • Vanc can also increase the risk of ototoxicity when used with other ototoxic drugs (AMGs, cisplatin, loop diuretics)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Telavancin and Oritavancin drug interactions

A
  • Tele: vibativ
  • Oritacancin: Orbactiv
  • Avoid televancin in patients with congenital long QT syndrom, known QT prolongation or uncompensated heart failure. Caution with other meds known to cause QT prolong
  • Orivancin is a weak inhibitor of 2C9 and 2C19, and a weak inducer of 3A4 and 2D6 use caution in warfarin and other drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Daptomycin MOA, and coverage

Cubicin

A
  • Binds to cell membrane components, causing rapid depolarization; this inhibits intracellular replication process including protein synthesis and causes cell death.
  • Concentration dependent activity
  • G+, Including staph (MRSA), enterococcus (bothe species of VRE) (E. Faecium and facalis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

When shouldnt daptomycin be used?

What is it approved for?

A

For pneumonia inactivated in the lungs by surfactant

  • complicated skin and soft tissue infections, S. Aureus (MRSA), bloodstream infections, including right sided endocarditis.
  • Dose adjustment at 30 CrCl
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Dapto warnings, SEs, Monitoring, and Notes

A
  • Eosinophilic pneumonia: generally developes 2-4 weeks after treatment
  • Myopathy and rhabdo: DC in pts with S/Sx and CPK >1000 units/L (5xULN), or in asymptomatic patients with CPK>= 2000 (10xULN)
  • Can falsely elevate INR/PT but does not increase bleed
  • SEs: Increased CPK,
  • Monitor: CPK weekly
  • Cubicin: compatible with NS and LR (no dextrose)
  • Cubicin RF: compatible with NS but must only use sterile or bacteriostatic water for injection,
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Dapto drug interactions only one

A
  • Increase muscle toxicity when used with statins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Oxazalidinones: wht are the drugs, the MOA, and coverage

A
  • Linezolid (Zyvox), Tedizolid (Sivextro)
  • Bind to 50s ribosomal subunit inhibiting translation and protein synthesis
  • Coverage similar to vanc but also cover all VREs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Linezolid dosing, contraindications, warning, SEs, monitoring and notes

A
  • No renal adjustment
  • IV:PO 1:1
  • Do not use within 2 wks of an MAO
  • Warnings: duration related myelosuppresion (thrombocytopenia, anemia, leukpenia)
  • Optic neuropathy when used for longer than 28 days
  • Serotonin syndrome
  • hypoglycemia
  • Increased BP
  • SEs: decreased platelets Hgb, WBC, Increased LFTs
  • Monitor: HR, BP weekly CBC
  • DO not shake linezolid suspension
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Linezolid and Redizolif drug interactions

A
  • They are reversible monoamine oxidase inhibitors, avoid tyramine containing food and serotonergic drugs
  • Linezolid can exacerbate hypoglycemic episodes, caution in patient receiving insulin or oral hypoglycemic drugs (sulfonylureas)
17
Q

Streptogrammin drug: MOA, coverage

What is it approved for?

A
  • Quinupristin/Dalfopristin (synercid)
  • binds to 50s subunit inhibiting protein synthesis
  • Covers most gram +, including MRSA and E. Faecium (not faecalis)
  • Complicated skin and soft tissue infections but not well tolerated so typically only used for VRE Faecium
18
Q

Synercid Notes

and Interactions

A
  • Quinu/Dalfro
  • Athralgias and Myalgias in up to 47% of pts
  • Infusion reactions including edema and pain
  • Hyperbilirubinmia, CPK elevation, Increased LFTs
  • Notes
    • D5W only
    • admin via central line such a PICC to avoid phlebitis
  • Interactions:
    • weak 3A4 inhibitor it can increase levels of CCBs, cyclosporine, dofetilide and others
19
Q

Glycycline drug: MOA, coverage, and treatment approval

A
  • Tigecycline (Tygacil)
  • Binds to 30S subunit inhibiting protein synthesis
  • Structurally related to tertracyclines
  • Broad g+, including MRSA and enterococcus
  • G-, bacteria, anaerobes and atypicals
  • HAS NO ACTIVITY AGAINST the 3Ps (Pseudomonas, Proteus, Providencia)
  • Complicated skin and soft tissue infections, intraabdominal infections, and CAP use is limited why?
20
Q

Tigecycline notes:

and DIs

A
  • Tygacil
  • Boxed warning increased risk of death, only use when absolutely have to
  • Hepatotoxic, pancreatitis, photosensitiivty, teath discoloration in children <8
  • Notes
    • Do not use for blood stream infections: not enough concentration
    • Reconstituted solution should be yellow-orange DC if not
  • DI: increase INR in patients taking warfarin
21
Q

What are the polymyxins what are there MOA,

Coverage

A
  • Colistimethate (sometimes called colistin) Coly-Mycin M
    • inactive prodrug that is hydrolyzed to colistin. Cationic detergent and damages the bacterial cytoplasmic membrane causing leakage and cell death
  • Polymyxins cover gram negative bacteria like (Enterobacter, E. Coli, Klebsiella, Pseudomonas, does not cover proteus
  • Due to toxicity risk they are primarily used for MDR gram-negative pathogens in combination with another abx
22
Q

Coly-Mycin M

A
  • CrCl<80 dose adjustment
  • Solution for inhalation must be mixed immediately prior to administration
  • Warnings:
    • Dose dependent nephrotoxocity, neurotoxicity (dizziness)
  • Notes:
    • prodrug that is converted to colistin, assess dose carefully
    • Avoid use with other nephrotoxic meds
    • Neurotoxicity can result in respiratory paralysis from neuromuscular blockade
23
Q

Polymxyin B sulfate

A

Boxed warnings

  • Dose dep nephrotoxicity
  • Neurotoxicity
  • Safety in pregnancy not established
  • Only in hospital
  • Neurotox can result in respiratory paralysis

Monitor renal function

1 mg = 10000 units of polymyxin B

24
Q

Polymyxin Drug interactions

A
  • Other nephro drugs (AMGs, cisplatin, AmphoB)
25
Chloramphenicol MOA, and coverage Notes as well
* Revesibly binds to 50S * G+, G-, anaerobes, and atypicals * Boxed Warnings * Serious and fatal blood dyscrasias (aplastic anemia, pancypenia, may be reverisble * Warniings: * Gray syndrome with high serum concentrations * G6PD deficiency * Monitoring: CBC at baseline and every 2 days, LFTs, renal function, serum drug concentrations
26
Clindamycin MOA, coverage
* Lincosamide which reversibly binds to the 30S * Covers aerobic and anaerobic g+ including (CAP MRSA) does not cover enterococcus or gram negative pathogens
27
Cleocin Notes
* Topical form * No dosage adjustments in renal impairment * Boxed warning * C.Diff colitis * Warning * Severe or fatal skin rxn (SJS/TEN/DRESS) * SEs: * N/V/D * Notes; * An induction test (D-test) should be performed on S. Aureus that is susceptible to clindamycin but resistant to erythromycin a **flattened zone** between the disks (positive D test) indicates inducible clindamycin resistance and clindamycin should not be used * Common uses: purulent and non-purulent skin infections, beta lactam alternative for dental abcess
28
Metronidazole and related meds: Which ones, MOA, coverage
* Metronidazole (flagyl) topical and vaginal, Tinidazole, Secnidazole * cause loss of helical DNA structure and strand breakage resulting in inhibition of protein synth * Metro covers: anaerobes and protazoal infections * Effective for bacterial vaginosis, trichomoniasis, giardisis, amebiasis, C.Diff, and is used in combination regimens for intraabdominal infections
29
Tinidazole coverage Secnidazole
* Acitivity limited to protozoa (giardiasis, amebiasis), trichomoniasis, and bacterial vaginosis * Secnidazole only indicated for bacterial vaginosis
30
Metronidazole and Tinidazole notes
* Metro IV:PO 1:1, Take with food * Boxed Warnings: * Possible carcinogenic based on animal data * Contraindications * pregnancy 1st trimester, use of alcohol or propylene glycol-containing products during treatment or within 3 days of tx DC (disulfram reaction) * Metro: use of disulfram within the past 2 wks * Tinidazole: breastfeeding * SEs: metallic taste, dark urine, SJS/TEN
31
Secnidazole (Solosec) Notes:
* Possibly carcinogenic * SEs * Vulvovaginal candidiasis, HA, N/V
32
Metro (flagyl) and Tinidazole drug interactions
* Metro Weak 3A4 and 2C9 inhibitor * Tinidazole: minor substrate of 3A4 * Both should not be used with alcohol during and for 3 days after DCing * Metronidazole (flagyl ) and potentially tinidazole, can increase INR in patients taking warfarin
33
Fidaxomicin Every thing
Inhibits RNA polymerase resulting in inhibition of protein synthesis It is used to treat C.Diff * Dificid * Warnings: Not effective for systemic infections
34
Rifaximin
Inhibits RNA synthesis by binding to DNA dep RNA polymerase, structurally related to Rifampin. Covers E.Coli
35
Rifaximin Indications and Notes:
* Travelers diarrhea, reduction of hepatic encephalopathy recurrence, IBS with diarrhea * Not effective for systemic infections * Used as salvage treatment for
36
Fosfomycin MOA and Coverage
* Inhibits bacterial cell wall synthesis by inactivating the enzyme pyruval transferase. Covers, E.Coli (including ESBLs) and E.Faecalis (including VRE) * A single dose regimen is used for uncomplicated UTIs (cystitis only) * FEmale uncomplicated UTIs
37
Nitrofurantoin Coverage MOA and notes
* Bacterial cell wall inhibitor it is used for uncomplicated UTIs (cystitis only. Covers E. COli, Klebsiella, Enterobacter, S. Aureus, and enterococcus (VRE) * Macrobid * Contrainfications: * Renal impairment \<60: not enough urinary concentrations * Warnings: * hemolytic anemia (detected with a positive coombs test) use caution in patients with G6PD deficiency * SEs: * GI upset (take with food), brown urine discoloration (harmless)
38
Nitrofurantoin (Macrobid) Take aways
* DOC for uncomplicated UTIs, * Do not use: Contraindicated in CrCl\<60 * Dosing * Macrobid BID * Macrodantin QID * Counseling * Take with food * Can discolor urine
39
Topical Decolonization What is it used for?
* Mupirocin nasal ointment (Bactroban) * Used to eliminate staph (MRSA) colonization of the nares